Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Novartis' Entresto: Slow Uptake Expected Following Fast FDA Approval

Executive Summary

Reimbursement complexity and physician reluctance to move stable patients off their current treatment regimens are the biggest hurdles.


Related Content

Amgen, Cytokinetics Checked With Payers Before Taking Omecamtiv Into Phase III
Novartis Accentuates The Positives Of Heart Failure Drug Entresto At ACC
FDA Review Of Novartis' Entresto Shows Agency's Practical Side
Novartis' Entresto Blockbuster Status On Track After CHMP Backing
Entresto Risk Sharing Could Equate To 8.6% Discount, ICER Says; Is Express Scripts Interested?
Bayer’s Finerenone Marches Forward, But Is Phase III Design Too Steep A Hill?
Novartis Talks Up Potential Blockbusters
Keeping Track: Two New BLAs, Two Line Extensions And One Advisory Committee
Novartis Takes Stock Of Ilaris For Gout Following FDA's Complete Response Letter


Related Companies